老视的药物治疗策略

Overview of pharmacological treatment strategies for presbyopia

老视的药物治疗未来有可能成为有别于框架眼镜、且易于使用的一种替代方法。目前主要有三类药物即缩瞳剂、晶状体软化剂和屈光功能调节剂在进行研发。缩瞳剂通过产生针孔效应,可增加不同工作距离的聚焦深度而治疗老视。缩瞳剂的作用均是暂时的,常见的不良事件包括头痛和夜间视力下降,尚无长期疗效和安全性数据公布。目前已有关于缩瞳剂与其他药物联合使用以达到累加治疗效果或减少不良事件的研究在开展。但这些联合作用疗效尚不清楚。本综述对老视的药物治疗领域的一些进展进行汇总。

Pharmacological treatment of presbyopia has the potential to become an alternative that is distinct from spectacles and easy to use in the future.At present,there are three main types of drugs-miotic agents,lens softeners and refractive function modulators in the research and development.Miotic agents treat presbyopia by producing a pinhole effect that increases the depth of focus at all working distances.The effects of miotic agents are transient,common adverse events include headache and nocturnal vision loss,and long-term efficacy and safety data are not available.There have been studies in which miotic agents have been used in combination with other drugs to achieve an additive therapeutic effect or to reduce adverse events.However,these combined effects are unknown.The aim of this review is to summarize some recent advances in the pharmacological treatment for presbyopia.